What development phase is LUBABEGRON in?

LUBABEGRON is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

LUBABEGRON

FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	LUBABEGRON
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LUBABEGRON CI brief — competitive landscape report
LUBABEGRON updates RSS · CI watch RSS